Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Indoles
  • Kidney Neoplasms
  • Nephrectomy
  • Pyrroles

abstract

  • Among patients with locoregional clear-cell renal-cell carcinoma at high risk for tumor recurrence after nephrectomy, the median duration of disease-free survival was significantly longer in the sunitinib group than in the placebo group, at a cost of a higher rate of toxic events. (Funded by Pfizer; S-TRAC ClinicalTrials.gov number, NCT00375674 .).

publication date

  • December 8, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1611406

PubMed ID

  • 27718781

Additional Document Info

start page

  • 2246

end page

  • 2254

volume

  • 375

number

  • 23